Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the latest results from ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostatic cancer.
Karim Fizazi, MD, PhD
Joaquin Mateo, MD, PhD
Released: April 19, 2021

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

  • PARP inhibitors combined with androgen receptors
  • Phase III trials of PARP inhibitors with androgen receptor–directed therapy
  • PARP inhibitors combined with immunotherapy
  • PARP inhibitors and DNA damaging agents

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer Inc.

Related Content

Updated analysis of rate of bone fractures in phase III EORTC GUCG 1333/PEACE-3 trial with or without BPAs from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Downloadable slideset covering PARP inhibitor monotherapy and determinants of response in metastatic CRPC, from Clinical Care Options (CCO)

person default Wassim Abida, MD, PhD Released: June 15, 2021

Downloadable slideset reviewing the rationale for PARP inhibitor combinations in metastatic CRPC, from Clinical Care Options (CCO)

Joaquin Mateo, MD, PhD Released: June 15, 2021

Results of phase III VISION trial with 177Lu-PSMA-617 + SOC vs SOC in metastatic castration-resistant prostate cancer from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue